Blue Bird BLBD 深 沪
等待开盘 11-25 09:30:00 美东时间
54.86
+1.040
+1.93%
华盛通- 最 高55.49
- 今 开54.00
- 成交量 86.35万股
- 最 低 52.70
- 昨 收 53.82
- 总市值 17.39亿
- 52周最高 61.95
- 市盈率 静 17.33
- 换手率 2.72%
- 52周最低 30.04
- 委 比 98.60%
- 总股本 3170.79万
- 历史最高 61.95
- 量 比 2.59
- 振 幅 5.18%
- 历史最低 7.135
- 每 手 1
- 风险率 8.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Blue Bird sets records for FQ4, reaffirms FY26 guidance
Blue Bird Corporation (BLBD) reported record profit and sales for the fiscal fourth quarter as the company delivered a record number of electric buses. The results beat Wall Street’s expectations and ...
今天 05:34
12 Industrials Stocks Moving In Monday's After-Market Session
Gainers Symbotic (NASDAQ:SYM) stock moved upwards by 9.6% to $60.79 during Mon...
今天 05:05
Blue Bird Sees FY2026 Sales $1.500B vs $1.452B Est
Blue Bird (NASDAQ:BLBD) sees FY2026 sales of $1.500 billion vs $1.452 billion analyst estimate.
今天 05:04
Blue Bird Q4 Adj. EPS $1.32 Beats $1.03 Estimate, Sales $409.400M Beat $380.372M Estimate
Blue Bird (NASDAQ:BLBD) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.03 by 27.66 percent. This is a 71.43 percent increase over earnings of $0.77 per share from the same
今天 05:02
Earnings Scheduled For November 24, 2025
Companies Reporting Before The Bell • Lotus Technology (NASDAQ:LOT) is likely t...
11-24 19:11
A Glimpse of Blue Bird's Earnings Potential
Blue Bird (NASDAQ:BLBD) is gearing up to announce its quarterly earnings on Mon...
11-21 23:00
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
DA Davidson Maintains Buy on Blue Bird, Maintains $70 Price Target
DA Davidson analyst Michael Shlisky maintains Blue Bird (NASDAQ:BLBD) with a Buy and maintains $70 price target.
11-21 00:16
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Needham Maintains Buy on Blue Bird, Raises Price Target to $70
Needham analyst Chris Pierce maintains Blue Bird (NASDAQ:BLBD) with a Buy and raises the price target from $53 to $70.
11-03 19:33
